Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
grade D 16.32 4.68% 0.73
VCEL closed up 4.68 percent on Friday, August 16, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical VCEL trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 4.68%
Below Lower BB Weakness 4.68%
Oversold Stochastic Weakness 4.68%
Lower Bollinger Band Walk Weakness 2.13%
Below Lower BB Weakness 2.13%

Older signals for VCEL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biopharmaceutical Medical Specialties Stem Cells Cell Therapy Burns Knee Cartilage Severe Diseases
Is VCEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.0
52 Week Low 10.51
Average Volume 473,221
200-Day Moving Average 17.4992
50-Day Moving Average 18.0868
20-Day Moving Average 18.116
10-Day Moving Average 17.286
Average True Range 0.819
ADX 24.05
+DI 17.4364
-DI 31.575
Chandelier Exit (Long, 3 ATRs ) 17.323
Chandelier Exit (Short, 3 ATRs ) 17.697
Upper Bollinger Band 20.3451
Lower Bollinger Band 15.8869
Percent B (%b) 0.1
BandWidth 24.609185
MACD Line -0.5921
MACD Signal Line -0.2512
MACD Histogram -0.3409
Fundamentals Value
Market Cap 535.67 Million
Num Shares 32.8 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -15.69
Price-to-Sales 2.75
Price-to-Book 10.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.40
Resistance 3 (R3) 17.31 16.87 17.22
Resistance 2 (R2) 16.87 16.59 16.91 17.16
Resistance 1 (R1) 16.59 16.42 16.73 16.68 17.10
Pivot Point 16.15 16.15 16.22 16.19 16.15
Support 1 (S1) 15.87 15.87 16.01 15.96 15.54
Support 2 (S2) 15.43 15.70 15.47 15.48
Support 3 (S3) 15.15 15.43 15.42
Support 4 (S4) 15.24